Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
An. bras. dermatol ; 97(5): 566-574, Sept.-Oct. 2022. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1403147

ABSTRACT

Abstract Background: Clinical studies have demonstrated that IL-17A inhibition with secukinumab is effective for clearing the skin of patients with psoriasis and has a favorable safety profile. Objective: The authors aim to determine whether secukinumab is effective and safe for the treatment of moderate-to-severe chronic psoriasis based on clinical experience with this drug. Method: The authors conducted a multicenter retrospective study in nine referral centers and included patients with psoriasis who had received secukinumab between March 2018 to November 2020. Data on demographic characteristics, Psoriasis Area and Severity Index (PASI) scores, and previous treatments were collected from medical records. Patients were evaluated at 12, 24, and 52 weeks with respect to response to treatment and side effects. Results: In total, 229 patients were recruited for the study. A PASI score improvement of ≥90 points over the baseline was achieved by 79%, 69.8%, and 49.3% of patients at weeks 12, 24, and 52, respectively. The most common adverse events wereCandida infections and fatigue. In total, 74 (32%) patients discontinued treatment by week 52, including due to adverse events, or secondary ineffectiveness. Study limitations: Retrospective design. Conclusions: These findings suggest that secukinumab therapy is reasonably effective in patients with moderate-to-severe psoriasis. Comorbidities and time length of the disease can affect the response to treatment. The rates of adverse events were high in this patient population.

2.
An. bras. dermatol ; 92(3): 404-406, May-June 2017. graf
Article in English | LILACS | ID: biblio-886970

ABSTRACT

Abstract Acute generalized exanthematous pustulosis is a rare drug-induced eruption that is characterized by acute, nonfollicular sterile pustules on an erythematous and edematous base. The most frequently implicated drugs are beta-lactam antibiotics. Hydroxychloroquine has been widely used to treat dermatologic and rheumatologic diseases and has been reported as a rare cause of acute generalized exanthematous pustulosis. A 42-year-old female presented with pustular lesions on the skin surface with erythema, facial edema, and occasional atypical target-like lesions after 21 days of treatment with 200mg/day hydroxychloroquine for rheumatoid arthritis, diagnosed one month previously. We report a case with acute generalized exanthematous pustulosis induced by hydroxychloroquine and treated with dapsone and systemic corticosteroid.


Subject(s)
Humans , Female , Adult , Antirheumatic Agents/adverse effects , Acute Generalized Exanthematous Pustulosis/etiology , Hydroxychloroquine/adverse effects , Arthritis, Rheumatoid/drug therapy , Antirheumatic Agents/therapeutic use , Acute Generalized Exanthematous Pustulosis/diagnosis , Hydroxychloroquine/therapeutic use
3.
An. bras. dermatol ; 91(6): 770-775, Nov.-Dec. 2016. tab
Article in English | LILACS | ID: biblio-837970

ABSTRACT

Abstract BACKGROUND: Vitiligo is an acquired pigmentary skin disorder that affects 0.5% to 2.0% of the population. OBJECTIVE: Patients' knowledge, opinions, and attitudes about vitiligo were evaluated. METHODS: The team conducted a cross-sectional, descriptive, prospective study between June 2014 and May 2015. The study included 100 patients aged over 12 years who were diagnosed with vitiligo. A questionnaire including items on knowledge, opinions, and beliefs about vitiligo and the Illness Perception Questionnaire (IPQ) were filled out by the patients, and the results were analyzed. RESULTS: In total, 100 (58 female, 42 male) patients were included in the study. Of them, 74% knew the name of their disease, 90% thought that vitiligo was not contagious, 48% reported that they obtained information on the disease from a doctor, and 69% believed they had adequate information on vitiligo. Eighty percent reported no negative effects from vitiligo on relationships with friends or family. It was believed that stress, excessive sun exposure, and heredity were causes of vitiligo, according to 84%, 37%, and 22% of the patients, respectively. Thirty-six patients (36%) believed that their illness was a serious disease and 35% deemed that it did not have a major impact on their lives. CONCLUSIONS: Our results show that vitiligo patients were generally highly aware of their condition. The disease did not negatively affect patient opinions or attitudes about vitiligo. The authors believe that improving patient-physician communication will impact positively on the course of the disease.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Young Adult , Self Concept , Vitiligo/psychology , Health Knowledge, Attitudes, Practice , Turkey , Sex Factors , Cross-Sectional Studies , Prospective Studies , Surveys and Questionnaires , Age Factors , Marital Status , Statistics, Nonparametric , Sickness Impact Profile , Culture , Educational Status
4.
An. bras. dermatol ; 91(5,supl.1): 64-65, Sept.-Oct. 2016. graf
Article in English | LILACS | ID: biblio-837964

ABSTRACT

Abstract Inducible urticaria is a heterogeneous subgroup of chronic urticarias caused by a wide variety of environmental stimuli, such as exercise, cold, heat, pressure, sunlight, vibration, and water. A new term, follicular traction urticaria, was suggested as an unusual form of inducible urticarias. We report a patient who was diagnosed with follicular traction urticaria.


Subject(s)
Humans , Female , Adult , Urticaria/etiology , Urticaria/pathology , Hair Follicle/pathology , Hair Removal/adverse effects , Time Factors , Chronic Disease
5.
Indian J Dermatol Venereol Leprol ; 2016 Sept-Oct; 82(5): 545-547
Article in English | IMSEAR | ID: sea-178473
7.
An. bras. dermatol ; 91(4): 442-445, July-Aug. 2016. tab, graf
Article in English | LILACS | ID: lil-792432

ABSTRACT

Abstract: Background: Vitiligo is an acquired pigmentary skin disorder affecting 0.1-4% of the general population. The nails may be affected in patients with an autoimmune disease such as psoriasis, and in those with alopecia areata. It has been suggested that nail abnormalities should be apparent in vitiligo patients. Objective: We sought to document the frequency and clinical presentation of nail abnormalities in vitiligo patients compared to healthy volunteers. We also examined the correlations between nail abnormalities and various clinical parameters. Methods: This study included 100 vitiligo patients and 100 healthy subjects. Full medical histories were collected from the subjects, who underwent thorough general and nail examinations. All nail changes were noted. In the event of clinical suspicion of a fungal infection, additional mycological investigations were performed. Results: Nail abnormalities were more prevalent in the patients (78%) than in the controls (55%) (p=0.001). Longitudinal ridging was the most common finding (42%), followed by (in descending order): leukonychia, an absent lunula, onycholysis, nail bed pallor, onychomycosis, splinter hemorrhage and nail plate thinning. The frequency of longitudinal ridging was significantly higher in patients than in controls (p<0.001). Conclusions: Nail abnormalities were more prevalent in vitiligo patients than in controls. Systematic examination of the nails in such patients is useful because nail abnormalities are frequent. However, the causes of such abnormalities require further study. Longitudinal ridging and leukonychia were the most common abnormalities observed in this study.


Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Aged , Young Adult , Vitiligo/epidemiology , Nails, Malformed/epidemiology , Turkey/epidemiology , Vitiligo/complications , Vitiligo/pathology , Case-Control Studies , Prevalence , Hypopigmentation/epidemiology , Statistics, Nonparametric , Nail Diseases/congenital , Nail Diseases/epidemiology , Nails, Malformed/etiology , Nails, Malformed/pathology
10.
Indian J Dermatol Venereol Leprol ; 2014 Jan-Feb; 80(1): 41-43
Article in English | IMSEAR | ID: sea-154744

ABSTRACT

Background: Macrolides are prescribed in the treatment of pityriasis rosea despite conflicting results of the limited number of studies evaluating their role in its treatment. Aim: A randomized double-blind placebo-controlled trial was conducted to evaluate the effect of azithromycin on the clinical course of pityriasis rosea. Methods: Seventy patients of pityriasis rosea were given either azithromycin (n = 35) or placebo (n = 35) and were followed-up at 2, 4 and 6 weeks. Pruritus was assessed in both groups using the visual analogue scale (VAS) . Change in the pityriasis rosea severity score (PRSS) and in the VAS were recorded as outcome measures and were compared statistically. Results: The decrease in PRSS from baseline through 2, 4 and 6 weeks within both treatment (P < 0.001) and placebo (P < 0.001) arms was found to be statistically significant; however, this change was not significantly different in the two groups (P = 0.179). Similarly, the decrease in VAS was found to be statistically significant within both groups (P < 0.001); however, the change was comparable between the two groups (P < 0.937). Analysis by Fisher's exact test did not find a significant difference between the two groups for PRSS and VAS. Conclusion: Azithromycin is not effective in pityriasis rosea and the use of macrolides for this disease should not be encouraged in clinical practice.


Subject(s)
Azithromycin/administration & dosage , Callosities/surgery , Humans , Minimally Invasive Surgical Procedures/methods , Pityriasis Rosea , Severity of Illness Index , Visual Analog Scale
12.
Indian J Dermatol Venereol Leprol ; 2009 May-June; 75(3): 303-304
Article in English | IMSEAR | ID: sea-140357
SELECTION OF CITATIONS
SEARCH DETAIL